Azimuth Capital Investment Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Azimuth Capital Investment Management acquired 11,696 Regeneron shares worth approximately $7.3 million in the second quarter, joining other institutional investors; hedge funds and institutions own 83.31% of the stock.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $800.36. Regeneron also exceeded quarterly expectations, reporting $14.29 in EPS and $4.29 billion in revenue, up 16.7% year over year.
• Shares opened at $827.72, near their 52-week high, while insiders have sold $3.43 million of stock over the past three months under pre-arranged trading plans; the company also faces potential legal and reputational risks tied to allegations concerning its Fianlimab-Libtayo trial.

Azimuth Capital Investment Management LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,696 shares of the biopharmaceutical company's stock, valued at approximately $7,293,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after acquiring an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at $226,000. Arrowstreet Capital Limited Partnership purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at $3,183,000. Gabelli Funds LLC grew its position in Regeneron Pharmaceuticals by 3.0% during the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company's stock worth $978,000 after purchasing an additional 55 shares during the period. Finally, Sei Investments Co. grew its position in Regeneron Pharmaceuticals by 18.8% during the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company's stock worth $16,985,000 after purchasing an additional 5,120 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald boosted their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an "overweight" rating in a report on Friday, July 31st. Citigroup raised their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a report on Monday, August 3rd. Wall Street Zen upgraded Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 15th. Canaccord Genuity Group decreased their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating for the company in a report on Tuesday, May 19th. Finally, Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a "hold" rating in a research report on Wednesday, July 29th. Fourteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $800.36.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Recent commentary continues to view Regeneron as a potentially attractive long-term biotech investment, supported by its established commercial portfolio, development pipeline and strong financial profile. However, the comparison with Vertex reportedly gives Vertex the clearer near-term investment edge. Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
• Neutral Sentiment: Regeneron’s Phase 1/2 study combining cemiplimab with SNS-101 has been completed, providing a pipeline milestone, although no efficacy or regulatory results were released. Cemiplimab Combination Trial Completion
• Negative Sentiment: Several law firms are recruiting investors for a securities class action alleging that Regeneron and certain executives misled shareholders about the viability and risks of the Phase 3 Fianlimab-Libtayo trial, including its protocol change and failure to meet the primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates potential reputational, legal and financial risks. Regeneron Class Action Deadline Alert
• Negative Sentiment: Director Kathryn Guarini sold 400 shares for $340,000, while EVP Marion McCourt sold 2,346 shares for approximately $2.0 million. All sales were made under pre-arranged Rule 10b5-1 plans, reducing their value as discretionary bearish signals, but the transactions may weigh on sentiment near recent highs. SEC Insider Transaction Filing

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,215 shares of the company's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares in the company, valued at $11,163,900. This represents a 8.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 4,146 shares of company stock valued at $3,432,488. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $827.72 on Friday. The firm has a market cap of $85.22 billion, a PE ratio of 20.46, a P/E/G ratio of 1.62 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $859.34. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $738.29 and a 200 day moving average price of $720.10.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period last year, the company earned $12.81 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 16.7% compared to the same quarter last year. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source